SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Aug 5, 2021
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Aug. 5, 2021 · CIK: 0001607678 · Accession: 0001564590-21-041580
AI Filing Summary & Sentiment
File numbers found in text: 333-258231
Letter
vktx-corresp.htm
12340 El Camino Real, Suite 250
San Diego, CA 92130
August 5, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Attention: Jessica Ansart
100 F Street, N.E.
Washington, D.C. 20549
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 28, 2021
File No. 333-258231
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-258231) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on July 28, 2021, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on August 11, 2021 or as soon thereafter as may be practicable.
The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Registrant hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm vktx-corresp.htm 12340 El Camino Real, Suite 250 San Diego, CA 92130 August 5, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jessica Ansart 100 F Street, N.E. Washington, D.C. 20549 Re: Viking Therapeutics, Inc. Registration Statement on Form S-3 Filed July 28, 2021 File No. 333-258231 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-258231) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on July 28, 2021, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on August 11, 2021 or as soon thereafter as may be practicable. The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Registrant hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration. Sincerely, VIKING THERAPEUTICS, INC. By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer cc:Samantha H. Eldredge, Esq. (Paul Hastings LLP)